Results 21 to 30 of about 3,281 (174)

Use of Romiplostim during pregnancy as a rescue therapy in primary immune thrombocytopenia: Literature review and case description

Platelets, 2020
Thrombocytopenia could appear during pregnancy, in up to 8–10% of the cases, where 3–5% is related to an autoimmune process so-called immune thrombocytopenia (ITP). We present a 34-year-old woman debuted at 13 weeks gestation, with a platelet count of 19 
Rodriguez Nuñez Rosa María, Rubio Lacambra Laura, Palomo Bravo Ángeles, Langenhorst Baniandres Laura   +3 more
doaj   +2 more sources

PATIENTS WITH ≥ 20 X 109/L PLATELETS AT BASELINE MAY HAVE A PROMPT RESPONSE TO ROMIPLOSTIM DURING THE EARLY PHASE OF TREATMENT: AN ITALIAN SINGLE-INSTITUTION EXPERIENCE

Mediterranean Journal of Hematology and Infectious Diseases, 2012
Patients with chronic immune thrombocytopenia treated with romiplostim may benefit from a higher starting dose when a rapid increase in count is needed, but it could be avoided in those with a prompt response to the standard dosage.
Simone Baldini, Luigi Rigacci, Valentina Carrai, Renato Alterini, Rajmonda Fjerza, Alberto Bosi   +5 more
doaj   +2 more sources

Myelofibrosis Associated with Romiplostim Treatment in a Patient with Immune Thrombocytopenia

Case Reports in Hematology, 2012
Immune thrombocytopenia is characterized by antibody-mediated platelet destruction and insufficient platelet production resulting in isolated thrombocytopenia in the absence of underlying cause.
Maria Fernanda Gonzalez, Jonathan King Freeman   +1 more
doaj   +4 more sources

Aplastic anemia with thrombopoietin gene mutation successfully treated with romiplostim monotherapy

Indian Pediatrics Case Reports, 2023
Background: Eltrombopag and romiplostim are thrombopoietin-receptor agonists (TPO-RA), which are approved globally for the treatment of immune thrombocytopenia.
Niranjan Gurunath Hegde, Deenadayalan Munirathnam, Meena Sivasankaran, Ravikumar Thangadorai   +3 more
doaj   +1 more source

Quality of Life Changes in Patients with Chronic Immune Thrombocytopenia in the Process of Romiplostim Therapy, its Efficacy and Safety in the Real-World Setting: Results of a Multi-Center Observational Study

Клиническая онкогематология, 2023
Aim. To study the quality of life in patients with chronic immune thrombocytopenia (ITP) in the process of romiplostim therapy and to assess the efficacy and safety of this drug in real-world setting. Materials & Methods.
T. I. Ionova, O. Yu. Vinogradova, T. V. Shelekhova, D. G. Sherstnev, A. V. Proidakov, E. V. Lyyurova, M. M. Pankrashkina, L. A. Mukha, E. E. Markova, N. V. Novitskaya, T. I. Pospelova, T. N. Babaeva, N. B. Bulieva, G. B. Kuchma, E. A. Andreevskaya, E. E. Zinina, M. V. Frolova, K. B. Trizna, I. L. Shestopalova, T. V. Shneider, S. A. Volkova, S. G. Zakharov, I. I. Mulina, I. E. Solov’eva, A. A. Myasnikov, A. A. Kuchin, L. B. Khvorostenko, N. M. Porfirieva, Tatyana Pavlovna Nikitina, V. V. Ptushkin, S. V. Gritsaev   +30 more
doaj   +1 more source

Safety and efficacy of romiplostim in children and adolescents with Immune thrombocytopenia: A systematic review

Hematology, Transfusion and Cell Therapy, 2023
Objective: To evaluate the efficacy and safety of romiplostim (thrombopoietin-receptor agonist) in the treatment of pediatric immune thrombocytopenia (ITP).
Fernanda Lubiana de Oliveira, Fernanda Silva Sequeira, Marlene Pereira Garanito   +2 more
doaj   +1 more source

Romiplostim for chemotherapy‐induced thrombocytopenia: Efficacy and safety of extended use

Research and Practice in Thrombosis and Haemostasis, 2022
Background Chemotherapy‐induced thrombocytopenia (CIT) is common during treatment with antineoplastic therapies and may adversely impact chemotherapy dose intensity. There is no approved therapy for CIT.
Cy R. Wilkins, Jocelyn Ortiz, Leah J. Gilbert, Shen Yin, Jodi V. Mones, Rekha Parameswaran, Simon Mantha, Gerald A. Soff   +7 more
doaj   +1 more source

Open-label pilot study of romiplostim for thrombocytopenia after autologous hematopoietic cell transplantation

, 2023
There are no standard treatments to prevent or hasten the recovery from severe conditioning-regimen-induced thrombocytopenia occurring after autologous hematopoietic cell transplantation (auto-HCT).
Perales, Miguel-Angel, Scordo, Michael, Soff, Gerald A., Giralt, Sergio A., Hanley, Danielle M., Landau, Heather J., Ruiz, Josel D., Chung, David J., Dahi, Parastoo B., Flynn, Jessica R., Nguyen, Linh K., Devlin, Sean M., Lahoud, Oscar B., Sauter, Craig S., Gilbert, Leah J., Shah, Gunjan L., Lin, Richard J.   +16 more
core   +1 more source

Role of romiplostim in splenectomized and nonsplenectomized patients with immune thrombocytopenia [PDF]

, 2016
Jose Perdomo Hematology Research Unit, St George and Sutherland Clinical School, University of New South Wales, Kogarah, NSW, Australia Abstract: Romiplostim is a thrombopoietin receptor agonist (TPO-RA) used for the treatment of adult primary immune ...
Perdomo, J ; https://orcid.org/, Perdomo J   +1 more
core   +1 more source

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide

Journal of Hematology & Oncology, 2012
Background Lenalidomide treatment in myelodysplastic syndrome (MDS) may lead to thrombocytopenia and dose reductions/delays. This study evaluated the safety and tolerability of the thrombopoietin mimetic romiplostim and its effects on the incidence of ...
Wang Eunice S, Lyons Roger M, Larson Richard A, Gandhi Sunil, Liu Delong, Matei Carmen, Scott Bart, Hu Kuolung, Yang Allen S   +8 more
doaj   +1 more source